The practical impact of pharmacoeconomics on institutional managers (Q41018882)

Pharmacoeconomics: Theory into Practice. Applying the Concepts to Today’s Issues

25 September 2017

0 references

title

The practical impact of pharmacoeconomics on institutional managers (English)

1 reference

25 September 2017

Cooke J

1

1 reference

25 September 2017

1 October 1994

1 reference

25 September 2017

1 reference

25 September 2017

6

1 reference

25 September 2017

289-297

1 reference

25 September 2017

4

1 reference

https://scigraph.springernature.com/pub.10.2165/00019053-199406040-00002

25 September 2017

0 references

cites work

Some interim results from a controlled trial of cost sharing in health insurance

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

A clinician's guide to cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Clinical economics. A guide to the economic analysis of clinical practices

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

On the decision rules of cost-effectiveness analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Seventeen years' experience of a voluntarily based drug rationalisation programme in hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Hospital formularies: need for continuous intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Cost of hospital antimicrobial chemotherapy. A method for global cost calculation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Economics of home intravenous services

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Prescribing in Europe--forces for change

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Economic Analysis Alongside Clinical Trials: Revisiting the Methodological Issues

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Epidemiological model and cost-effectiveness analysis of tuberculosis treatment programmes in Indonesia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Tuberculosis: commentary on a reemergent killer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Immunisation and herd immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

"Not clinically indicated": patients' interests or resource allocation?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

A cost-effectiveness study of the management of intractable urinary incontinence by urinary catheterisation or incontinence pads

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

How can we design trials to detect clinically important changes in disease severity?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

The economics of cholesterol lowering

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Cost and health implications of cholesterol lowering

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

How-often-that-high graphs of serum cholesterol. Findings from the Scottish Heart Health and Scottish MONICA studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Coronary heart disease is not preventable by population interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

The epidemiology of hypercholesterolemia. A global perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Dietary reduction of serum cholesterol concentration: time to think again

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Risk factors for ischaemic heart disease in British men

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Hospital care for elderly patients with diseases of the circulatory system. A comparison of hospital use in the United States and Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Modelling the Helsinki Heart Study by means of risk equations obtained from the PROCAM Study and the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Should there be a moratorium on the use of cholesterol lowering drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

A scale for assessing quality of life in adult asthma sufferers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

A scale for the measurement of quality of life in adults with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

The validity of health assessments: resolving some recent differences

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Sensitivity of quality of life domains and constructs to longitudinal change in a clinical trial comparing salmeterol with placebo in asthmatics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Salmeterol: an inhaled beta 2-agonist with prolonged duration of action

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Selection of items and avoidance of bias in quality of life scales.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

The MOS 36-ltem Short-Form Health Survey (SF-36)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Measuring the economic costs of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

The economic costs of schizophrenia. Implications for public policy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

The economic burden of depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Economic aspects of patterns of mental health care: cost variation by setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Expenditures for psychotropic medications in the United States in 1985.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

A comparative trial of home and hospital psychiatric care. One-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Alternative to mental hospital treatment. II. Economic benefit-cost analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Psychiatric hospital versus community treatment: the results of a randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Community orientated treatment compared to psychiatric hospital orientated treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Schizophrenia. A comparative trial of community orientated and hospital orientated psychiatric care.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Cost of schizophrenia in a randomized trial of home-based treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Day hospitalization and an inn instead of inpatient care for psychiatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

The evaluation of a hostel ward. A controlled study using modified cost-benefit analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

The cost of schizophrenia revisited.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

A ward in a house: accommodation for "new' long-stay patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Day treatment and psychotropic drugs in the aftercare of schizophrenic patients. A Veterans Administration cooperative study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Cost of anxiety disorders: impact of comorbidity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Prescribing selective serotonin reuptake inhibitors as strategy for prevention of suicide

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens: a hospital perspective from Italy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Cost effectiveness of inhaled corticosteroid plus bronchodilator therapy versus bronchodilator monotherapy in children with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-specific Lung Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Cost-effectiveness of drug therapy for hypercholesterolaemia: a review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Statistical versus quantitative significance in the socioeconomic evaluation of medicines

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

Foundations of Cost-Effectiveness Analysis for Health and Medical Practices

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199406040-00002

10.2165/00019053-199406040-00002

21 January 2018

Identifiers

DOI

reason for deprecated rank

does not exactly match

0 references

Dimensions Publication ID

0 references

1 reference

PubMed ID

10147466